Molecular Pathology of Pituitary Adenomas

Molecular Pathology of Pituitary Adenomas

Volumn , Issue , 2012, Pages

  Tanase, Cristiana ^a   Ogrezeanu, Irina ^b   Badiu, Corin ^c  

^a VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

^b Neurosurgical Clinical I   (Romania)

^c CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85013714493     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/C2011-0-04253-9     Document Type: Book

References (318)

1. Saeger W., Ludecke D.K., Buchfelder M., Fahlbusch R., Quabbe H.J., Petersenn S. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur. J. Endocrinol. 2007, 156:203-216.
2. Melmed S. Update in pituitary disease. J. Clin. Endocrinol. Metab. 2008, 93:331-338.
3. Buurman H., Saeger W. Subclinical adenomas in postmortem pituitaries: Classification and correlations to clinical data. Eur. J. Endocrinol. 2006, 154:753-758.
4. Chidiac R.M., Aron D.C. Incidentalomas. A disease of modern technology. Endocrinol. Metab. Clin. North Am. 1997, 26:233-253.
5. Molitch M.E. Pituitary tumours: Pituitary incidentalomas. Best. Pract. Res. Clin. Endocrinol. Metab. 2009, 23:667-675.
6. Vernooij M.W., Ikram M.A., Tanghe H.L., Vincent A.J., Hofman A., Krestin G.P., et al. Incidental findings on brain MRI in the general population. N. Engl. J. Med. 2007, 357:1821-1828.
7. Ezzat S., Asa S.L., Couldwell W.T., Barr C.E., Dodge W.E., Vance M.L., et al. The prevalence of pituitary adenomas: A systematic review. Cancer 2004, 101:613-619.
8. Levy A. Stem cells, hormones, and pituitary adenomas. J. Neuroendocrinol. 2008, 20:139-140.
9. Xu Q., Yuan X., Tunici P., Liu G., Fan X., Xu M., et al. Isolation of tumour stem-like cells from benign tumours. Br. J. Cancer 2009, 101:303-311.
10. Scheithauer B., Horvath E., Kovacs K., Lloyd R.V. Tumours of the adenohypophysis. International Histological Classification of Tumours: Histological Typing of Endocrine Tumours 2004, 15-28. Springer-Verlag, Berlin. E. Solcia, G. Klöppel, L.H. Sobin (Eds.).
11. Asa S.L., Ezzat S. The pathogenesis of pituitary tumors. Annu. Rev. Pathol. 2009, 4:97-126.
12. Perry A., Scheithauer B.W. Commentary: Classification and grading of pituitary tumors. Observations of two working neuropathologists. Acta Neuropathol. 2006, 111:68-70.
13. Colao A., Vitale G., Cappabianca P., Briganti F., Ciccarelli A., De R.M., et al. Outcome of cabergoline treatment in men with prolactinoma: Effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J. Clin. Endocrinol. Metab. 2004, 89:1704-1711.
14. Colao A., Loche S., Cappa M., Di S.A., Landi M.L., Sarnacchiaro F., et al. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. J. Clin. Endocrinol. Metab. 1998, 83:2777-2780.
15. D'Ercole M., Della Pepa G.M., Carrozza C., Bianchi A., Doglietto F. Two diagnostic pitfalls mimicking a prolactin-secreting microadenoma. J. Clin. Endocrinol. Metab. 2010, 95:5171.
16. Vallette-Kasic S., Morange-Ramos I., Selim A., Gunz G., Morange S., Enjalbert A., et al. Macroprolactinemia revisited: A study on 106 patients. J. Clin. Endocrinol. Metab. 2002, 87:581-588.
17. Asa S.L., Horvath E., Kovacs K. Pituitary neoplasms: An overview of the clinical presentation, diagnosis, treatment and pathology. Endocrine Tumors 1993, 77-112. Blackwell Scientific Publications, Boston, MA. E.L. Mazzaferri, N.A. Samaan (Eds.).
18. Torre D.L., Falorni A. Pharmacological causes of hyperprolactinemia. Ther. Clin. Risk Manag. 2007, 3:929-951.
19. Gillam M.P., Molitch M.E., Lombardi G., Colao A. Advances in the treatment of prolactinomas. Endocr. Rev. 2006, 27:485-534.
20. Martin N.M., Tan T., Meeran K. Dopamine agonists and hyperprolactinaemia. BMJ 2009, 338:b381.
21. Fleseriu M., Lee M., Pineyro M.M., Skugor M., Reddy S.K., Siraj E.S., et al. Giant invasive pituitary prolactinoma with falsely low serum prolactin: The significance of "hook effect". J. Neurooncol. 2006, 79:41-43.
22. Fernandez A., Karavitaki N., Wass J.A. Prevalence of pituitary adenomas: A community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin. Endocrinol. (Oxf.) 2010, 72:377-382.
23. Arafah B.M., Nasrallah M.P. Pituitary tumors: Pathophysiology, clinical manifestations and management. Endocr. Relat. Cancer 2001, 8:287-305.
24. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull. Johns Hopkins Hosp. 1932, 50:137-195.
25. de Bruin C., Pereira A.M., Feelders R.A., Romijn J.A., Roelfsema F., Sprij-Mooij D.M., et al. Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J. Clin. Endocrinol. Metab. 2009, 94:1118-1124.
26. Sanno N., Teramoto A., Osamura R.Y., Horvath E., Kovacs K., Lloyd R.V., et al. Pathology of pituitary tumors. Neurosurg. Clin. N. Am. 2003, 14:25-39.
27. Vezina J.L., Hardy J., Yamashita M. Microadenomas and hypersecreting pituitary adenomas. Arq. Neuropsiquiatr. 1975, 33:119-127. [article in Portuguese].
28. Knosp E., Steiner E., Kitz K., Matula C. Pituitary adenomas with invasion of the cavernous sinus space: A magnetic resonance imaging classification compared with surgical findings. Neurosurgery 1993, 33:610-617.
29. Chacko G., Chacko A.G., Lombardero M., Mani S., Seshadri M.S., Kovacs K., et al. Clinicopathologic correlates of giant pituitary adenomas. J. Clin. Neurosci. 2009, 16:660-665.
30. Bailey P. Pathological report of a case of acromegaly, with special reference to the lesions in the hypophysis cerebri and in the thyroid gland; and a case of haemorrhage in to the pituitary. Philadelphia Med. J. 1898, 1:789-792.
31. Wakai S., Fukushima T., Teramoto A., Sano K. Pituitary apoplexy: Its incidence and clinical significance. J. Neurosurg. 1981, 55:187-193.
32. Rajasekaran S., Vanderpump M., Baldeweg S., Drake W., Reddy N., Lanyon M., et al. UK guidelines for the management of pituitary apoplexy. Clin. Endocrinol. (Oxf.) 2011, 74:9-20.
33. Semple P.L., Jane J.A., Laws E.R. Clinical relevance of precipitating factors in pituitary apoplexy. Neurosurgery 2007, 61:956-961.
34. Randeva H.S., Schoebel J., Byrne J., Esiri M., Adams C.B., Wass J.A. Classical pituitary apoplexy: Clinical features, management, and outcome. Clin. Endocrinol. (Oxf.) 1999, 51:181-188.
35. Bills D.C., Meyer F.B., Laws E.R., Davis D.H., Ebersold M.J., Scheithauer B.W., et al. A retrospective analysis of pituitary apoplexy. Neurosurgery 1993, 33:602-608.
36. Ayuk J., McGregor E.J., Mitchell R.D., Gittoes N.J. Acute management of pituitary apoplexy-surgery or conservative management?. Clin. Endocrinol. (Oxf.) 2004, 61:747-752.
37. Sibal L., Ball S.G., Connolly V., James R.A., Kane P., Kelly W.F., et al. Pituitary apoplexy: A review of clinical presentation, management, and outcome in 45 cases. Pituitary 2004, 7:157-163.
38. Leyer C., Castinetti F., Morange I., Gueydan M., Oliver C., Conte-Devolx B., et al. A conservative management is preferable in milder forms of pituitary tumor apoplexy. J. Endocrinol. Invest. 2010, 33.
39. Gruber A., Clayton J., Kumar S., Robertson I., Howlett T.A., Mansell P. Pituitary apoplexy: Retrospective review of 30 patients-is surgical intervention always necessary?. Br. J. Neurosurg. 2006, 20:379-385.
40. Maccagnan P., Macedo C.L., Kayath M.J., Nogueira R.G., Abucham J. Conservative management of pituitary apoplexy: A prospective study. J. Clin. Endocrinol. Metab. 1995, 80:2190-2197.
41. Zayour D.H., Selman W.R., Arafah B.M. Extreme elevation of intrasellar pressure in patients with pituitary tumor apoplexy: Relation to pituitary function. J. Clin. Endocrinol. Metab. 2004, 89:5649-5654.
42. Turgut M., Ozsunar Y., Basak S., Guney E., Kir E., Meteoglu I. Pituitary apoplexy: An overview of 186 cases published during the last century. Acta Neurochir. (Wien.) 2010, 152:749-761.
43. Fraser L.A., Lee D., Cooper P., Van Uum S. Remission of acromegaly after pituitary apoplexy: Case report and review of literature. Endocr. Pract. 2009, 15:725-731.
44. Gheorghiu M.L., Baculescu N., Dumitrascu A., Purice M., Coculescu M. Acromegaly remission after spontaneous pituitary adenoma apoplexy. Acta Endocrinol. (Buc.) 2006, 2:495. [abstract].
45. Gheorghiu M.L., Niculescu D., Dumitrascu A., Coculescu M. Pituitary stone in long-standing acromegaly with spontaneous remission. Acta Endocrinol. (Buc.) 2008, 4:203-210.
46. Kamiya Y., Jin-No Y., Tomita K., Suzuki T., Ban K., Sugiyama N., et al. Recurrence of Cushing's disease after long-term remission due to pituitary apoplexy. Endocr. J. 2000, 47:793-797.
47. Randall B.R., Couldwell W.T. Apoplexy in pituitary microadenomas. Acta Neurochir. (Wien.) 2010, 152:1737-1740.
48. Kontogeorgos G. Classification and pathology of pituitary tumors. Endocrine 2005, 28:27-35.
49. Obari A., Sano T., Ohyama K., Kudo E., Qian Z.R., Yoneda A., et al. Clinicopathological features of growth hormone-producing pituitary adenomas: Difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr. Pathol. 2008, 19:82-91.
50. Horvath E., Kovacs K. Morphogenesis and significance of fibrous bodies in human pituitary adenomas. Virchows Arch. B Cell Pathol. 1978, 27:69-78.
51. Wade A.N., Baccon J., Grady M.S., Judy K.D., O'Rourke D.M., Snyder P.J. Clinically silent somatotroph adenomas are common. Eur. J. Endocrinol. 2011, 165:39-44.
52. Psaras T., Honegger J., Buslei R., Saeger W., Klein D., Capper D., et al. Atypical type II silent corticotrophic adenoma developing into Cushing's disease upon second recurrence. Exp. Clin. Endocrinol. Diabetes 2007, 115:610-615.
53. Erickson D., Scheithauer B., Atkinson J., Horvath E., Kovacs K., Lloyd R.V., et al. Silent subtype 3 pituitary adenoma: A clinicopathologic analysis of the Mayo Clinic experience. Clin. Endocrinol. (Oxf.) 2009, 71:92-99.
54. Fazekas I., Hegedus B., Bacsy E., Kerekes E., Slowik F., Balint K., et al. Characterization of human pituitary adenomas in cell cultures by light and electron microscopic morphology and immunolabeling. Folia Histochem. Cytobiol. 2005, 43:81-90.
55. Coculescu M., Badiu C., Galoiu S., Caragheorgheopol A., Stancu C., Morris J. Evolution under complex therapy of acromegaly due to a pituitary plurihormonal adenoma with colocalisation of GH and FSH. Acta Endocrinol. (Buc.) 2006, 2:337-348.
56. Al-Sharim M., Scheithauer B.W., Horvath E., Kovacs K., Smyth H., Coire C., et al. Plurihormonal gonadotroph cell pituitary adenoma: Report of a unique case. Clin. Neuropathol. 2009, 28:182-187.
57. Kageyama K., Ikeda H., Nigawara T., Sakihara S., Suda T. Expression of adrenocorticotropic hormone, prolactin and transcriptional factors in clinically nonfunctioning pituitary adenoma. Endocr. J. 2007, 54:961-968.
58. Chacko G., Chacko A.G., Lombardero M., Mani S., Seshadri M.S., Kovacs K., et al. Clinicopathologic correlates of giant pituitary adenomas. J. Clin. Neurosci. 2009, 16:660-665.
59. Badiu C., Dumbrava M., Stancu C., Ciubotaru V., Coculescu M. Immunoreactivity for glycoproteic hormones and tumor size in pituitary adenomas. Acta Endocrinol. (Buc.) 2006, 2:1-9.
60. Saccomanno K., Spada A., Bassetti M., Gil-del-Alamo P., Faglia G. Immunodetection of chorionic gonadotrophin and its subunits in human nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab. 1994, 78:1103-1107.
61. Katznelson L., Alexander J.M., Bikkal H.A., Jameson J.L., Hsu D.W., Klibanski A. Imbalanced follicle-stimulating hormone beta-subunit hormone biosynthesis in human pituitary adenomas. J. Clin. Endocrinol. Metab. 1992, 74:1343-1351.
62. Al-Shraim M., Asa S.L. The 2004 World Health Organization classification of pituitary tumors: What is new?. Acta Neuropathol. 2006, 111:1-7.
63. Naritaka H., Kameya T., Sato Y., Furuhata S., Otani M., Kawase T. Morphological characterization and subtyping of silent somatotroph adenomas. Pituitary 1999, 1:233-241.
64. Diehl S., Weber T., Hamester U., Saeger W., Ludecke D.K. Light microscopical morphometric classification of oncocytic and chromophobe pituitary adenomas. Exp. Clin. Endocrinol. 1988, 91:341-349.
65. Nishioka H., Ito H., Hirano A., Kato Y. Immunocytochemical demonstration of oncocytes in normal adenohypophysis. Acta Neuropathol. 1999, 97:40-44.
66. Nishioka H., Ito H., Hirano A. Immunohistochemical demonstration of oncocytes in nongonadotrophic pituitary adenomas. Virchows Arch. 1999, 435:428-433.
67. Niveiro M., Aranda F.I., Paya A., Boix E., Peiro G., Pico A. Oncocytic transformation in pituitary adenomas: Immunohistochemical analyses of 65 cases. Arch. Pathol. Lab. Med. 2004, 128:776-780.
68. Desai B., Burrin J.M., Nott C.A., Geddes J.F., Lamb E.J., Aylwin S.J., et al. Glycoprotein hormone alpha-subunit production and plurihormonality in human corticotroph tumours-an in vitro and immunohistochemical study. Eur. J. Endocrinol. 1995, 133:25-32.
69. Kuerbitz S.J., Plunkett B.S., Walsh W.V., Kastan M.B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. U.S.A. 1992, 89(16):7491-7495.
70. Molecular Pathology of the Pituitary 2004, Karger, Basel. G. Kontogeorgos, K. Kovacs (Eds.).
71. Turner H.E., Nagy Z., Sullivan N., Esiri M.M., Wass J.A.H. Expression analysis of cyclines in pituitary adenomas and the normal pituitary gland. Clin. Endocrinol. (Oxf.) 2000, 53:337-344.
72. Tani Y., Inoshita N., Sugiyama T., Kato M., Yamada S., Shichiri M., et al. Upregulation of CDKN2A and suppression of cyclin D1 gene expressions in ACTH-secreting pituitary adenomas. Eur. J. Endocrinol. 2010, 163(4):523-529.
73. Jordan S., Lidhar K., Korbonits M., Lowe D.G., Grossman A.B. Cyclin D and cyclin E expression in normal and adenomatous pituitary. Eur. J. Endocrinol. 2000, 143:R1-R6.
74. Yu R., Melmed S. Pathogenesis of pituitary tumors. Prog. Brain Res. 2010, 182:207-227.
75. Nakabayashi H., Sunada I., Hara M. Immunohistochemical analyses of cell cycle-related proteins, apoptosis, and proliferation in pituitary adenomas. J. Histochem. Cytochem. 2001, 49:1193-1194.
76. Klencki M., Kurnatowska I., Slowinska-Klencka D., Lewinski A., Pawlikowski M. Correlation between PCNA expression and AgNOR dots in pituitary adenomas. Endocr. Pathol. 2001, 12:163-169.
77. Prevedello D.M., Jagannathan J., Jane J.A., Lopes M.B., Laws E.R. Relevance of high Ki-67 in pituitary adenomas. Case report and review of the literature. Neurosurg. Focus 2005, 19:E11.
78. Delgrange E., Trouillas J., Maiter D., Donckier J., Tourniaire J. Sex-related difference in the growth of prolactinomas: A clinical and proliferation marker study. J. Clin. Endocrinol. Metab. 1997, 82:2102-2107.
79. Fainstein D.P., Glerean M., Lovazzano S., Pietrani M., Christiansen S., Balzaretti M., et al. Gender differences in macroprolactinomas: Study of clinical features, outcome of patients, and ki-67 expression in tumor tissue. Front. Horm. Res. 2010, 38:50-58.
80. Losa M., Franzin A., Mangili F., Terreni M.R., Barzaghi R., Veglia F., et al. Proliferation index of nonfunctioning pituitary adenomas: Correlations with clinical characteristics and long-term follow-up results. Neurosurgery 2000, 47:1313-1318.
81. Tanaka Y., Hongo K., Tada T., Sakai K., Kakizawa Y., Kobayashi S. Growth pattern and rate in residual nonfunctioning pituitary adenomas: Correlations among tumour volume doubling time, patient age, and MIB-1 index. J. Neurosurg. 2003, 98:359-365.
82. Noh T.W., Jeong H.J., Lee M.K., Kim T.S., Kim S.H., Lee E.J. Predicting recurrence of nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab. 2009, 94(11):4406-4413.
83. Ruebel K.H., Jin L., Zhang S.Y., Scheithauer B.W., Lloyd R.V. Inactivation of the p16 gene in human pituitary nonfunctioning tumors by hypermethylation is more common in null cells adenomas. Endocr. Pathol. 2001, 12:281-289.
84. Gaffey T.A., Scheithauer B.W., Lloyd R.V., Burger P.C., Robbins P., Fereidooni F., et al. Corticotroph carcinoma of the pituitary: A clinicopathological study. J. Neurosurg. 2002, 96:352-360.
85. Korbonits M., Chahal H.S., Kaltsas G., Jordan S., Urmanova Y., Khalimova Z., et al. Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. J. Clin. Endocrinol. Metab. 2002, 87:2635-2643.
86. Nakabayashi H., Sunada I., Hara M. Immunohistochemical analyses of cell cycle-related proteins, apoptosis, and proliferation in pituitary adenomas. J. Histochem. Cytochem. 2001, 49:1193-1194.
87. Stefaneanu L., Kovacs K., Scheithauer B.W., Kontogeorgos G., Reihle D.L., Sebo T.J., et al. Effect of dopamine agonists on lactotroph adenomas of the human pituitary. Endocr. Pathol. 2000, 11:341-352.
88. Liu W., Asa S.L., Ezzat S. Vitamin D and its analog EB1089 induce p27 accumulation and diminish association of p27 with Skp2 independent of PTEN in pituitary corticotroph cells. Brain Pathol. 2002, 12:412-419.
89. Thapar K., Scheithauer B.W., Kovacs K., Pernicone P.J., Laws E.R. p53 expression in pituitary adenomas and carcinomas: Correlation with invasiveness and tumor growth fractions. Neurosurgery 1997, 38(4):765-770. ; discussion 770-1.
90. Wierinckx A., Auger C., Devauchelle P., Reynaud A., Chevallier P., Jan M., et al. A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocr. Relat. Cancer 2007, 14(3):887-900.
91. Gaffey T.A., Scheithauer B.W., Lloyd R.V., Burger P.C., Robbins P., Fereidooni F., et al. Corticotroph carcinoma of the pituitary: A clinicopathological study. J. Neurosurg. 2002, 96:352-360.
92. Roncaroli F., Scheithauer B.W., Young W.F., Horvath E., Kovacs K., Kros J.M., et al. Silent corticotroph carcinoma of the adenohypophysis-A report of five cases. Am. J. Surg. Pathol. 2003, 27:477-486.
93. Cohen A.B., Lessell S. Angiogenesis and pituitary tumors. Semin. Ophthalmol. 2009, 24(3):185-189.
94. Kerbel R.S. Tumor angiogenesis. N. Engl. J. Med. 2008, 358(19):2039-2049.
95. Ciccarelli A., Daly A.F., Beckers A. The epidemiology of prolactinomas. Pituitary 2005, 8(1):3-6.
96. Niveiro M., Aranda F.I., Peiró G., Alenda C., Picó A. Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas. Hum. Pathol. 2005, 36(10):1090-1095.
97. Turner H.E., Nagy Z., Gatter K.C., Esiri M.M., Harris A.L., Wass J.A. Angiogenesis in pituitary adenomas-relationship to endocrine function, treatment and outcome. J. Endocrinol. 2000, 165(2):475-481.
98. Di Ieva A., Grizzi F., Ceva-Grimaldi G., Russo C., Gaetani P., Aimar E., et al. Fractal dimension as a quantitator of the microvasculature of normal and adenomatous pituitary tissue. J. Anat. 2007, 211(5):673-680.
99. Takada K., Yamada S., Teramoto A. Correlation between tumor vascularity and clinical findings in patients with pituitary adenomas. Endocr. Pathol. 2004, 15(2):131-139.
100. de la Torre N.G., Wass J.A., Turner H.E. Morphologic changes and molecular regulation of angiogenesis in pituitary adenomas. Front. Horm. Res. 2004, 32:133-145.
101. Fukui S., Nawashiro H., Otani N. Vascular endothelial growth factor expression in pituitary adenomas. Acta Neurochir. Suppl. 2003, 86:519-521.
102. Fukui S., Otani N., Nawashiro H. The association of the expression of vascular endothelial growth factor with the cystic component and haemorrhage in pituitary adenoma. J. Clin. Neurosci. 2003, 10(3):320-324.
103. McCabe C.J., Boelaert K., Tannahill L.A. Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J. Clin. Endocrinol. Metab. 2002, 87(9):4238-4244.
104. Salehi F., Agur A., Scheithauer B.W., Kovacs K., Lloyd R.V., Cusimano M. Biomarkers of pituitary neoplasms: A review (part II). Neurosurgery 2010, 67(6):1790-1798.
105. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997, 277:48-50.
106. Oliner J., Min H., Leal J., Yu D., Rao S., You E., et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004, 6:507-516.
107. Gruszka A., Kunert-Radek J., Pawlikowski M. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with pituitary adenomas. Pituitary 2005, 8(2):163-168.
108. Fukui S., Otani N., Nawashiro H., Yano A., Nomura N., Miyazawa T., et al. Subcellular localization of basic fibroblast growth factor and fibroblast growth factor receptor 1 in pituitary adenomas. Brain Tumor Pathol. 2002, 19(1):23-29.
109. Qian Z.R., Sano T., Asa S.L., Yamada S., Horiguchi H., Tashiro T., et al. Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: Relation to tumor type, size, proliferation, and invasiveness. J. Clin. Endocrinol. Metab. 2004, 89(4):1904-1911.
110. McCabe C.J., Khaira J.S., Boelaert K., Heaney A.P., Tannahill L.A., Hussain S., et al. Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: Relationships to clinical tumour behaviour. Clin. Endocrinol. (Oxf.) 2003, 58(2):141-150.
111. Kim K., Yoshida D., Teramoto A. Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in pituitary adenomas. Endocr. Pathol. 2005, 16(2):115-121.
112. Vidal S., Horvath E., Kovacs K., Kuroki T., Lloyd R.V., Scheithauer B.W. Expression of hypoxia-inducible factor-1alpha (HIF-1alpha) in pituitary tumours. Histol. Histopathol. 2003, 18(3):679-686.
113. Onguru O., Scheithauer B.W., Kovacs K., Vidal S., Jin L., Zhang S., et al. Analysis of Cox-2 and thromboxane synthase expression in pituitary adenomas and carcinomas. Endocr. Pathol. 2004, 15(1):17-27.
114. Bloomer C.W., Kenyon L., Hammond E., Hyslop T., Andrews D.W., Curran W.J., et al. Cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) expression in human pituitary macroadenomas. Am. J. Clin. Oncol. 2003, 26(4):S75-S80.
115. Vidal S., Kovacs K., Bell D., Horvath E., Scheithauer B.W., Lloyd R.V. Cyclooxygenase-2 expression in human pituitary tumors. Cancer 2003, 97(11):2814-2821.
116. Hussaini I.M., Trotter C., Zhao Y., Abdel-Fattah R., Amos S., Xiao A., et al. Matrix metalloproteinase-9 is differentially expressed in nonfunctioning invasive and noninvasive pituitary adenomas and increases invasion in human pituitary adenoma cell line. Am. J. Pathol. 2007, 170(1):356-365.
117. Buchfelder M., Fahlbusch R., Adamse F., Kiesewetter F., Thierauf P. Proliferation parameters for pituitary adenomas. Acta Neurochir. 1996, 65:18-21.
118. Abdel-Moneim I., Melamed M.R., Darzynkiewicz Z., Gorczyca W. Proliferation and apoptosis in solid tumors. Anal. Quant. Cytol. Histol. 2000, 22(5):393-397.
119. Molecular Pathology of the Pituitary 2004, Karger, Basel. G. Kontogeorgos, K. Kovacs (Eds.).
120. Schwartz L.M., Osborne B.A. Programmed cell death, apoptosis and killer genes. Immunol. Today 1993, 14:582-590.
121. Fornas O., Mato M.E., Viader M., Oliver B., Tresserres P., Bartumeus F., et al. Flow cytometry analysis of pituitary adenomas. Horm Res. 1996, 46(6):257-262.
122. Kontogeorgos G., Sambaziotis D., Piaditis G., Karameris A. Apoptosis in human pituitary adenomas: A morphologic and in situ end-labeling study. Mod. Pathol. 1997, 10(9):921-926.
123. Kulig E., Jin L., Qian X., Horvath E., Kovacs K., Stefaneanu L., et al. Apoptosis in nontumorous and neoplastic human pituitaries-expression of the Bcl-2 family of proteins. Am. J. Pathol. 1999, 154:767-774.
124. Tanase, C., Codorean, E., Ardeleanu, C., Butur, G., Manda, G., Neagu, M., et al. (2004) Apoptosis in pituitary adenomas; Comparative study by flow cytometry and in situ end-labeling technique. In Second Intercontinental Congress of Pathology, Iguassu Falls, Brazil, June 9-13 (Soares, F., Vassallo, J., and Torres, L.F.B., eds). Medimond International Proceedings, Medimond-Monduzzi Editore, Italy, pp. 117-120,. http://www.monduzzi.com.
125. Schmitz I., Kirchkoff P.H. Regulation of death receptor-mediated apoptosis pathways. Int. J. Biochem. Cell Biol. 2000, 32:1123-1136.
126. Sambaziotis D., Kapranos N., Kontogeorgos G. Bcl-2 gene family in endocrine pathology: A review. Endocr. Pathol. 2000, 11:205-213.
127. Tamm I., Schriever F., Dorken B. Apoptosis: Implications of basic research for clinical oncology. Lancer Oncol. 2001, 2:33-42.
128. Reed J.C. Mechanisms of apoptosis. Am. J. Pathol. 2000, 157:1415-1430.
129. Losa M., Barzaghi R.L., Mortini P., Franzin A., Mangili F., Terreni M.R., et al. Determination of the proliferation and apoptotic index in adrenocorticotropin-secreting pituitary tumors: Comparison between micro- and macroadenomas. Am. J. Pathol. 2000, 156:245-251.
130. Losa M., Ciccarelli E., Mortini P., Barzaghi R., Gaia D., Faccani G., et al. Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas. J. Clin. Endocrinol. Metab. 2001, 86:5194-5200.
131. Vidal S., Horvath E., Kovacs K., Scheithauer B.W., Lloyd R.V., Kontogeorgos G. Ultrastructural features of apoptosis in human pituitary adenomas. Ultrastruct. Pathol. 2001, 25:85-92.
132. Messini I., Kontogeorgos G., Kovacs K., Horvath E., Smyth H.S. Pituitary corticotroph adenoma containing many apoptotic cells: A histologic, immunohistochemical, ultrastructural and molecular study. Ultrastruct. Pathol. 2002, 26:27-32.
133. Tanase C., Codorean E., Arsene D., Ardeleanu C., Raducan E., Popescu I.D., et al. APAF-1 and cathepsin-B, regulators of mitochondrial apoptotic pathway in pituitary tumor progression. Histopathology 2008, 53:219.
134. Grossman A.B. The molecular biology of pituitary tumours: A personal perspective. Pituitary 2009, 12(3):265-270.
135. Heaney A.P. Pituitary tumour pathogenesis. Br. Med. Bull. 2005, 75-76:81-97.
136. Yoshida D., Nomura R., Teramoto A. Regulation of cell invasion and signalling pathways in the pituitary adenoma cell line, HP-75, by reversion-inducing cysteine-rich protein with kazal motifs (RECK). J. Neurooncol. 2008, 89(2):141-150.
137. Vlotides G., Eigler T., Melmed S. Pituitary tumor-transforming gene: Physiology and implications for tumorigenesis. Endocr. Rev. 2007, 28(2):165-186.
138. Xu M., Shorts-Cary L., Knox A.J., Kleinsmidt-Demasters B., Lillehei K., Wierman M.E. Epidermal growth factor receptor pathway substrate 8 (Eps8) is over expressed in human pituitary tumours: Role in proliferation and survival. Endocrinology 2009, 150(5):2064-2071.
139. Tanase C.P., Neagu M., Albulescu R. Key signaling molecules in pituitary tumors. Expert. Rev. Mol. Diagn. 2009, 9(8):859-877.
140. Pertuit M., Barlier A., Enjalbert A., Gérard C. Signalling pathway alterations in pituitary adenomas: Involvement of Gsα, cAMP and mitogen-activated protein kinases. J. Neuroendocrinol. 2009, 21(11):869-877.
141. Picard C., Silvy M., Gerard C., Buffat C., Lavaque E., Figarella-Branger D., et al. Gsα overexpression and loss of Gsα imprinting in human somatotroph adenomas: Association with tumor size and response to pharmacologic treatment. Int. J. Cancer 2007, 121:1245-1252.
142. Naviglio S., Pagano M., Romano M., Sorrentino A., Fusco A., Illiano F., et al. Adenylate cyclase regulation via proteasome-mediated modulation of Gαs levels. Cell Signal. 2004, 16:1229-1237.
143. Weinstein L.S., Liu J., Sakamoto A., Xie T., Chen M. Minireview: GNAS: Normal and abnormal functions. Endocrinology 2004, 145:5459-5464.
144. Weinstein L.S., Chen M., Xie T., Liu J. Genetic diseases associated with heterotrimeric G proteins. Trends Pharmacol. Sci. 2006, 27:260-266.
145. Hayward B.E., Barlier A., Korbonits M., Grossman A.B., Jacquet P., Enjalbert A., et al. Imprinting of the G(s)α gene GNAS1 in the pathogenesis of acromegaly. J. Clin. Invest. 2001, 107:R31-R36.
146. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents. Pharmacol. Ther. 2006, 109:366-398.
147. Persani L., Borgato S., Lania A., Filopanti M., Mantovani G., Conti M., et al. Relevant cAMP-specific phosphodiesterase isoforms in human pituitary: Effect of Gs(α) mutations. J. Clin. Endocrinol. Metab. 2001, 86:3795-3800.
148. Peri A., Conforti B., Baglioni-Peri S., Luciani P., Cioppi F., Buci L., et al. Expression of cyclic adenosine 3′,5′-monophosphate (cAMP)-responsive element binding protein and inducible cAMP early repressor genes in growth hormone-secreting pituitary adenomas with or without mutations of the Gsα gene. J. Clin. Endocrinol. Metab. 2001, 86:2111-2117.
149. Romano D., Magalon K., Pertuit M., Rasolonjanahary R., Barlier A., Enjalbert A., et al. Conditional overexpression of the wild-type Gsα as the gsp oncogene initiates chronic extracellularly regulated kinase 1/2 activation and hormone hypersecretion in pituitary cell lines. Endocrinology 2007, 148:2973-2983.
150. Sakai N., Kim K., Sanno N., Yoshida D., Teramoto A., Shibasaki T. Elevation of growth hormone-releasing hormone receptor messenger ribonucleic acid expression in growth hormone-secreting pituitary adenoma with Gsα protein mutation. Neurol. Med. Chir. 2008, 48(11):481-487.
151. Asa S.L., Digiovanni R., Jiang J., Ward M.L., Loesch K., Yamada S., et al. A growth hormone receptor mutation impairs growth hormone autofeedback signalling in pituitary tumours. Cancer Res. 2007, 67(15):7505-7511.
152. Kontogeorgos G., Kovacs K. Molecular Pathology of the Pituitary 2004, Karger, Basel.
153. Theodoropoulou M., Zhang J., Laupheimer S., Paez-Pereda M., Erneux C., Florio T., et al. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signalling and inducing Zac1 expression. Cancer Res. 2006, 66(3):1576-1582.
154. Hubina E., Nanzer A.M., Hanson M.R., Ciccarelli E., Losa M., Gaia D., et al. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur. J. Endocrinol. 2006, 155(2):371-379.
155. Ferone D., Gatto F., Arvigo M., Resmini E., Boschetti M., Teti C., et al. The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology. J. Mol. Endocrinol. 2009, 42(5):361-370.
156. Naor Z. Signalling by G-protein-coupled receptor (GPCR): Studies on the GnRH receptor. Front. Neuroendocrinol. 2009, 30(1):10-29.
157. Dobkin-Bekman M., Naidich M., Pawson A.J., Millar R.P., Seger R., Naor Z. Activation of mitogen-activated protein kinase (MAPK) by GnRH is cell-context dependent. Mol. Cell Endocrinol. 2006, 252(1-2):184-190.
158. Kraus S., Levy G., Hanoch T., Naor Z., Seger R. Gonadotropin-releasing hormone induces apoptosis of prostate cancer cells: Role of c-Jun NH2-terminal kinase, protein kinase B, and extracellular signal-regulated kinase pathways. Cancer Res. 2004, 64(16):5736-5744.
159. Kraus S., Naor Z., Seger R. Gonadotropin-releasing hormone in apoptosis of prostate cancer cells. Cancer Lett. 2006, 234(2):109-123.
160. Maudsley S., Davidson L., Pawson A.J., Chan R., Lopez de Maturana R., Millar R.P. Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signalling in peripheral reproductive tumor cells by activating a Gαi-coupling state of the type I GnRH receptor. Cancer Res. 2004, 64(20):7533-7544.
161. Kim K.Y., Choi K.C., Park S.H., Auersperg N., Leung P.C. Extracellular signal-regulated protein kinase, but not c-Jun N-terminal kinase, is activated by type II gonadotropin-releasing hormone involved in the inhibition of ovarian cancer cell proliferation. J. Clin. Endocrinol. Metab. 2005, 90(3):1670-1677.
162. Massa A., Casagrande S., Bajetto A., Porcile C., Barbieri F., Thellung S., et al. SDF-1 controls pituitary cell proliferation through the activation of ERK1/2 and the Ca2+-dependent, cytosolic tyrosine kinase Pyk2. Ann. N. Y. Acad. Sci. 2006, 1090:385-398.
163. Liu W., Matsumoto Y., Okada M., Miyake K., Kunishio K., Kawai N., et al. Matrix metalloproteinase 2 and 9 expression correlated with cavernous sinus invasion of pituitary adenomas. J. Med. Invest. 2005, 52(3-4):151-158.
164. Gong J., Zhao Y., Abdel-Fattah R., Amos S., Xiao A., Lopes M.B., et al. Matrix metalloproteinase-9, a potential biological marker in invasive pituitary adenomas. Pituitary 2008, 11(1):37-48.
165. Hussaini I.M., Trotter C., Zhao Y., Abdel-Fattah R., Amos S., Xiao A., et al. Matrix metalloproteinase-9 is differentially expressed in nonfunctioning invasive and noninvasive pituitary adenomas and increases invasion in human pituitary adenoma cell line. Am. J. Pathol. 2007, 170(1):356-365.
166. Hazell G., Yao S., Roper J., Prossnitz E., O'Carroll A.M., Lolait S. Localisation of GPR30, a novel G-protein-coupled oestrogen receptor, suggests multiple functions in rodent brain and peripheral tissues. J. Endocrinol. 2009, 202(2):223-236.
167. Sakamoto H., Matsuda K., Hosokawa K., Nishi M., Morris J.F., Prossnitz E.R., et al. Expression of G-protein-coupled receptor-30, a G-protein-coupled membrane estrogen receptor, in oxytocin neurons of the rat paraventricular and supraoptic nuclei. Endocrinology 2007, 148(12):5842-5850.
168. Heaney A.P., Fernando M., Yong W.H., Melmed S. Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat. Med. 2002, 8(11):1281-1287.
169. Rey-Roldan E.B., Grillo C.A., Pietranera L., Libertun C., Nicola A.F., Piroli G.G. Levonorgestrel antagonism on estrogen-induced pituitary tumours is mediated by progesterone receptors. Horm. Metab. Res. 2008, 40(4):245-250.
170. Hunter J.A., Skelly R.H., Aylwin S.J., Geddes J.F., Evanson J., Besser G.M., et al. The relationship between pituitary tumour transforming gene (PTTG) expression and in vitro hormone and vascular endothelial growth factor (VEGF) secretion from human pituitary adenomas. Eur. J. Endocrinol. 2003, 148(2):203-211.
171. Boikos S.A., Stratakis C.A. Molecular genetics of the cAMP-dependent protein kinase pathway and of sporadic pituitary tumorigenesis. Hum. Mol. Genet. 2007, 16(1):R80-R87.
172. Salehi F., Kovacs K., Scheithaur B.W., Lloyd R.V., Cusimano M. Pituitary tumor-transforming gene in endocrine and other neoplasms: A review and update. Endocr. Relat. Cancer 2008, 15(3):721-743.
173. Wierinckx A., Auger C., Devauchelle P., Reynaud A., Chevallier P., Jan M., et al. A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumours. Endocr. Relat. Cancer 2007, 14(3):887-900.
174. Chamaon K., Kirches E., Kanakis D., Braeuninger S., Dietzmann K., Mawrin C. Regulation of the pituitary tumor transforming gene by insulin-like-growth factor-I and insulin differs between malignant and non-neoplastic astrocytes. Biochem. Biophys. Res. Commun. 2005, 331(1):86-92.
175. Hamid T., Kakar S.S. PTTG/securin activates expression of p53 and modulates its function. Mol. Cancer 2004, 3:18.
176. McCabe C.J., Boelaert K., Tannahill L.A., Heaney A.P., Stratford A.L., Khaira J.S., et al. Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumours. J. Clin. Endocrinol. Metab. 2002, 87(9):4238-4244.
177. Minematsu T., Suzuki M., Sanno N., Takekoshi S., Teramoto A., Osamura R.Y. PTTG over expression is correlated with angiogenesis in human pituitary adenomas. Endocr. Pathol. 2006, 17(2):143-153.
178. Filippella M., Galland F., Kujas M., Young J., Faggiano A., Lombardi G., et al. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: A clinical and immunohistochemical study. Clin. Endocrinol. (Oxf.) 2006, 65(4):536-543.
179. McCabe C.J., Khaira J.S., Boelaert K., Heaney A.P., Tannahill L.A., Hussain S., et al. Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: Relationships to clinical tumour behaviour. Clin. Endocrinol. (Oxf.) 2003, 58(2):141-150.
180. Kanakis D., Kirches E., Mawrin C., Dietzmann K. Promoter mutations are no major cause of PTTG over expression in pituitary adenomas. Clin. Endocrinol. (Oxf.) 2003, 58(2):151-155.
181. Vlotides G., Zitzmann K., Hengge S., Engelhardt D., Stalla G.K., Auernhammer C.J. Expression of novel neurotrophin-1/B-cell stimulating factor-3 (NNT-1/BSF-3) in murine pituitary folliculostellate TtT/GF cells: Pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide-induced stimulation of NNT-1/BSF-3 is mediated by protein kinase A, protein kinase C, and extracellular-signal-regulated kinase 1/2 pathways. Endocrinology 2004, 145(2):716-727.
182. Vlotides G., Cruz-Soto M., Rubinek T., Eigler T., Auernhammer C.J., Melmed S. Mechanisms for growth factor-induced pituitary tumor transforming gene-1 expression in pituitary folliculostellate TtT/GF cells. Mol. Endocrinol. 2006, 20(12):3321-3335.
183. Friday B.B., Adjei A.A. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin. Cancer Res. 2008, 14(2):342-346.
184. Fougner S.L., Bollerslev J., Latif F., Hald J.K., Lund T., Ramm-Pettersen J., et al. Low levels of raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment. J. Clin. Endocrinol. Metab. 2008, 93(4):1211-1216.
185. Jackson T.A., Koterwas D.M., Morgan M.A., Bradford A.P. Fibroblast growth factors regulate prolactin transcription via an atypical Rac-dependent signalling pathway. Mol. Endocrinol. 2003, 17(10):1921-1930.
186. Hamid T., Malik M.T., Millar R.P., Kakar S.S. Protein kinase A serves as a primary pathway in activation of Nur77 expression by gonadotropin-releasing hormone in the LβT2 mouse pituitary gonadotroph tumor cell line. Int. J. Oncol. 2008, 33(5):1055-1064.
187. Grossman A.B., Korbonits M. Akting and cycling: A tale of the pituitary. Horm. Res. 2004, 62(Suppl. 3):117-123.
188. Lu C., Willingham M.C., Furuya F., Cheng S.Y. Activation of phosphatidylinositol 3-kinase signalling promotes aberrant pituitary growth in a mouse model of thyroid-stimulating hormone-secreting pituitary tumours. Endocrinology 2008, 149(7):3339-3345.
189. Garcia-Echeverria C., Sellers W.R. Drug discovery approaches targeting the PI3K/AKT pathway in cancer. Oncogene 2008, 27(41):5511-5526.
190. Lin Y., Jiang X., Shen Y., Li M., Ma H., Xing M., et al. Frequent mutations and amplifications of the PIK3CA gene in pituitary tumours. Endocr. Relat. Cancer 2009, 16(1):301-310.
191. Quereda V., Malumbres M. Cell cycle control of pituitary development and disease. J. Mol. Endocrinol. 2009, 42(2):75-86.
192. Zhu X., Wang J., Ju B.G., Rosenfeld M.G. Signalling and epigenetic regulation of pituitary development. Curr. Opin. Cell Biol. 2007, 19(6):605-611.
193. Miyakoshi T., Takei M., Kajiya H., Egashira N., Takekoshi S., Teramoto A., et al. Expression of Wnt4 in human pituitary adenomas regulates activation of the β-catenin-independent pathway. Endocr. Pathol. 2008, 19(4):261-273.
194. Gueorguiev M., Grossman A.B. Pituitary gland and β-catenin signaling: From ontogeny to oncogenesis. Pituitary 2009, 12(3):245-255.
195. Elston M.S., Gill A.J., Conaglen J.V., Clarkson A., Shaw J.M., Law A.J., et al. Wnt pathway inhibitors are strongly down-regulated in pituitary tumours. Endocrinology 2008, 149(3):1235-1242.
196. Kremenevskaya, N., Khattak, M. and Buchfelder M. (2007) Activation of the Wnt 5A, β-catenin, TCF-4, cyclin D1 and E-cadherin in null cell pituitary adenomas. Poster presentation at the 89th Annual Meeting of the Endocrine Society, June 2-5, 2007, Toronto, Canada, P1-284.
197. Cañibano C., Rodriguez N.L., Saez C., Tovar S., Garcia-Lavandeira M., Borrello M.G., et al. The dependence receptor Ret induces apoptosis in somatotrophs through a Pit1/p53 pathway, preventing tumor growth. EMBO J. 2007, 26(8):2015-2028.
198. Malumbres M., Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem. Sci. 2005, 30(11):630-641.
199. Ramsey M.R., Krishnamurthy J., Pei X.H., Torrice C., Lin W., Carrasco D.R., et al. Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumours and tissues. Cancer Res. 2007, 67(10):4732-4741.
200. Ogino A., Yoshino A., Katayama Y., Watanabe T., Ota T., Komine C., et al. The p15(INK4b)/p16(INK4a)/RB1 pathway is frequently deregulated in human pituitary adenomas. J. Neuropathol. Exp. Neurol. 2005, 64(5):398-403.
201. Donangelo I., Marcos H.P., Araujo P.B., Marcondes J., Filho P.N., Gadelha M., et al. Expression of retinoblastoma protein in human growth hormone-secreting pituitary adenomas. Endocr. Pathol. 2005, 16(1):53-62.
202. Vierimaa O., Georgitsi M., Lehtonen R., Vahteristo P., Kokko A., Raitila A., et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006, 312:1228-1230.
203. Daly A.F., Vanbellinghen J.F., Khoo S.K., Jaffrain-Rea M.L., Naves L.A., Guitelman M.A., et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: Analysis in 73 families. J. Clin. Endocrinol. Metab. 2007, 92:1891-1896.
204. Toledo R.A., Lourenco D.M., Liberman B., Cunha-Neto M.B., Cavalcanti M.G., Moyses C.B., et al. Germline mutation in the aryl hydrocarbon receptor interacting protein gene in familial somatotropinoma. J. Clin. Endocrinol. Metab. 2007, 92:1934-1937.
205. Georgitsi M., De M.E., Cannavo S., Makinen M.J., Tuppurainen K., Pauletto P., et al. Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas. Clin. Endocrinol. (Oxf.) 2008, 69:621-627.
206. Polyak K., Li Y., Zhu H., Lengauer C., Willson J.K., Markowitz S.D., et al. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat. Genet. 1998, 20:291-293.
207. Romero F., Multon M.C., Ramos-Morales F., Dominguez A., Bernal J.A., Pintor-Toro J.A., et al. Human securin, hPTTG, is associated with Ku heterodimer, the regulatory subunit of the DNA-dependent protein kinase. Nucleic Acids Res. 2001, 29:1300-1307.
208. Sotillo R., Renner O., Dubus P., Ruiz-Cabello J., Martin-Caballero J., Barbacid M., et al. Cooperation between Cdk4 and p27kip1 in tumor development: A preclinical model to evaluate cell cycle inhibitors with therapeutic activity. Cancer Res. 2005, 65:3846-3852.
209. Heaney A.P., Fernando M., Melmed S. Functional role of estrogen in pituitary tumor pathogenesis. J. Clin. Invest. 2002, 109:277-283.
210. Paez-Pereda M., Kovalovsky D., Hopfner U., Theodoropoulou M., Pagotto U., Uhl E., et al. Retinoic acid prevents experimental Cushing syndrome. J. Clin. Invest. 2001, 108:1123-1131.
211. Hendriks-Stegeman B.I., Augustijn K.D., Bakker B., Holthuizen P., van der Vliet P.C., Jansen M. Combined pituitary hormone deficiency caused by compound heterozygosity for two novel mutations in the POU domain of the Pit1/POU1F1 gene. J. Clin. Endocrinol. Metab. 2001, 86:1545-1550.
212. Chanock S.J., Burdett L., Yeager M., Llaca V., Langerod A., Presswalla S., et al. Somatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomas. Breast Cancer Res. 2007, 9:R5.
213. Katoh M., Katoh M. Cross-talk of WNT and FGF signaling pathways at GSK3β to regulate β-catenin and SNAIL signaling cascades. Cancer Biol. Ther. 2006, 5:1059-1064.
214. Malumbres M., Pevarello P., Barbacid M., Bischoff J.R. CDK inhibitors in cancer therapy: What is next?. Trends Pharmacol. Sci. 2008, 29:16-21.
215. Waizenegger I., Gimenez-Abian J.F., Wernic D., Peters J.M. Regulation of human separase by securin binding and autocleavage. Curr. Biol. 2002, 12:1368-1378.
216. Botelho C.H., Magalhaes A.V., Mello P.A., Schmitt F.C., Casulari L.A. Expression of p53, Ki-67 and c-erb B2 in growth hormone-and/or prolactin-secreting pituitary adenomas. Arq. Neuropsiquiatr. 2006, 64:60-66.
217. Skelly R.H., Korbonits M., Grossman A., Besser G.M., Monson J.P., Geddes J.F., et al. Expression of the pituitary transcription factor Ptx-1, but not that of the trans-activating factor prop-1, is reduced in human corticotroph adenomas and is associated with decreased α-subunit secretion. J. Clin. Endocrinol. Metab. 2000, 85:2537-2542.
218. Pellegata N.S., Quintanilla-Martinez L., Siggelkow H., Samson E., Bink K., Hofler H., et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc. Natl. Acad. Sci. U.S.A 2006, 103:15558-15563.
219. Garcia-Echeverria C., Sellers W.R. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008, 27:5511-5526.
220. Skelly R.H., Korbonits M., Grossman A., Besser G.M., Monson J.P., Geddes J.F., et al. Expression of the pituitary transcription factor Ptx-1, but not that of the trans-activating factor prop-1, is reduced in human corticotroph adenomas and is associated with decreased α-subunit secretion. J. Clin. Endocrinol. Metab. 2000, 85(7):2537-2542.
221. Leng X., Noble M., Adams P.D., Qin J., Harper J.W. Reversal of growth suppression by p107 via direct phosphorylation by cyclin D1/cyclin-dependent kinase 4. Mol. Cell Biol. 2002, 22(7):2242-2254.
222. Garcia-Echeverria C., Sellers W.R. Drug discovery approaches targeting the PI3K/AKT pathway in cancer. Oncogene 2008, 27(41):5511-5526.
223. de Almeida J.P., Sherman J.H., Salvatori R., Quinones-Hinojosa A. Pituitary stem cells: Review of the literature and current understanding. Neurosurgery 2010, 67(3):770-780.
224. Vankelecom H. Stem cells in the postnatal pituitary?. Neuroendocrinology 2007, 85(2):110-130.
225. Nolan L.A., Levy A. A population of non-luteinising hormone/non-adrenocorticotrophic hormone-positive cells in the male rat anterior pituitary responds mitotically to both gonadectomy and adrenalectomy. J. Neuroendocrinol. 2006, 18(9):655-661.
226. Lepore D.A., Thomas G.P., Knight K.R., et al. Survival and differentiation of pituitary colony-forming cells in vivo. Stem Cells 2007, 25(7):1730-1736.
227. Vankelecom H., Gremeaux L. Stem cells in the pituitary gland: A burgeoning field. Gen. Comp. Endocrinol. 2010, 166(3):478-488.
228. Sills E.S., Takeuchi T., Tanaka N., Neri Q.V., Palermo G.D. Identification and isolation of embryonic stem cells in reproductive endocrinology: Theoretical protocols for conservation of human embryos derived from in vitro fertilization. Theor. Biol. Med. Model 2005, 2:25.
229. Vankelecom H. Non-hormonal cell types in the pituitary candidating for stem cell. Semin. Cell Dev. Biol. 2007, 18(4):559-570.
230. Horvath E., Kovacs K. Folliculostellate cells of the human pituitary: A type of adult stem cell?. Ultrastruct. Pathol. 2002, 26(4):219-228.
231. Horvath E., Coire C.I., Kovacs K., Smyth H.S. Folliculo-stellate cells of the human pituitary as adult stem cells: Examples of their neoplastic potential. Ultrastruct. Pathol. 2010, 34(3):133-139.
232. Devnath S., Inoue K. An insight to pituitary folliculo-stellate cells. J. Neuroendocrinol. 2008, 20(6):687-691.
233. Roncaroli F., Scheithauer B.W., Cenacchi G., et al. quot;Spindle cell oncocytoma" of the adenohypophysis: A tumor of folliculostellate cells?. Am. J. Surg. Pathol. 2002, 26(8):1048-1055.
234. Allaerts W., Vankelecom H. History and perspectives of pituitary folliculo-stellate cell research. Eur. J. Endocrinol. 2005, 153(1):1-12.
235. Krylyshkina O., Chen J., Mebis L., Denef C., Vankelecom H. Nestin-immunoreactive cells in rat pituitary are neither hormonal nor typical folliculo-stellate cells. Endocrinology 2005, 146(5):2376-2387.
236. Goodell M.A., Brose K., Paradis G., Conner A.S., Mulligan R.C. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med. 1996, 183(4):1797-1806.
237. Chen J., Gremeaux L., Fu Q., Liekens D., Van Laere S., Vankelecom H. Pituitary progenitor cells tracked down by side population dissection. Stem Cells 2009, 27(5):1182-1195.
238. Saeger W. Current pathological classification of pituitary adenomas. Acta. Neurochir. Suppl. 1996, 65:1-3.
239. Levy A. Stem cells, hormones and pituitary adenomas. J. Neuroendocrinol. 2008, 20(1):139-140.
240. Morrison S.J., Kimble J. Asymmetric and symmetric stem-cell divisions in development and cancer. Nature 2006, 441(7097):1068-1074.
241. Gleiberman A.S., Michurina T., Encinas J.M., et al. Genetic approaches identify adult pituitary stem cells. Proc. Natl. Acad. Sci. U.S.A. 2008, 105(17):6332-6337.
242. Xu Q., Yuan X., Tunici P., et al. Isolation of tumour stem-like cells from benign tumours. Br. J. Cancer 2009, 101(2):303-311.
243. Ishii Y., Suzuki M., Takekoshi S., et al. Immunonegative "null cell" adenomas and gonadotropin (Gn) subunit (SUs) immunopositive adenomas share frequent expression of multiple transcription factors. Endocr. Pathol. 2006, 17(1):35-43.
244. Hosoyama T., Nishijo K., Garcia M.M., et al. A postnatal Pax7 progenitor gives rise to pituitary adenomas. Genes Cancer 2010, 1(4):388-402.
245. Abbud R.A., Takumi I., Barker E.M., et al. Early multipotential pituitary focal hyperplasia in the alpha-subunit of glycoprotein hormone-driven pituitary tumor-transforming gene transgenic mice. Mol. Endocrinol. 2005, 19(5):1383-1391.
246. Albulescu R., Neagu M., Albulescu L., Tanase C. Tissular and soluble miRNAs for diagnostic and therapy improvement in digestive tract cancers. Expert Rev. Mol. Diagn. 2011, 11(1):101-120.
247. Zatelli M.C., degli Uberti E.C. MicroRNAs and possible role in pituitary adenomas. Semin. Reprod. Med. 2008, 26(6):453-460.
248. Bottoni A., Zatelli M.C., Ferracin M., Tagliati F., Piccin D., Vignali C. Identification of differentially expressed microRNAs by microarray: A possible role for microRNA genes in pituitary adenomas. J. Cell Physiol. 2007, 210:370-377.
249. Bottoni A., Piccin D., Tagliati F., Luchin A., Zatelli M.C., degli Uberti E.C. miR-15a and miR-16-1 downregulation in pituitary adenomas. J. Cell Physiol. 2005, 204:280-285.
250. Aqeilan R.I., Calin G.A., Croce C.M. XmiR-15a and miR-16-1 in cancer: Discovery, function and future perspectives. Cell Death Differ. 2010, 17(2):215-220.
251. Amaral F.C., Torres N., Saggioro F., Neder L., Machado H.R., Silva W.A. MicroRNAs differentially expressed in ACTH-secreting pituitary tumors. J. Clin. Endocrinol. Metab. 2009, 94:320-323.
252. Sivapragasam M., Rotondo F., Lloyd R.V., Scheithauer B.W., Cusimano M., Syro L.V., Kovacs K. MicroRNAs in the Human Pituitary. Endocr. Pathol. 2011, 22(3):134-143.
253. Qian Z.R., Asa S.L., Siomi H., Siomi M.C., Yoshimoto K., Yamada S. Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas. Mod. Pathol. 2009, 22(3):431-441.
254. Guo C.G., Sah J.F., Beard L., Willson J.K.V., Markowitz S.D., Guda K. The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer 2008, 47:939-946.
255. Salehi F., Kovacs K., Scheithauer B.W., Lloyd R.V., Cusimano M. Pituitary tumor transforming gene in endocrine and other neoplasms: A review and update. Endocr. Relat. Cancer 2008, 15:721-743.
256. Mao Z.G., He D.S., Zhou J., Yao B., Xiao W.W., Chen C.H. Differential expression of microRNAs in GH-secreting pituitary adenomas. Diagn. Pathol. 2010, 5:79.
257. Stilling G., Sun Z., Zhang S., Jin L., Righi A., Kovacs G. MicroRNA expression in ACTH-producing pituitary tumors: Up-regulation of microRNA-122 and -493 in pituitary carcinomas. Endocrine 2010, 38(1):67-75.
258. Esquela-Kerscher A., Slack F.J. Oncomirs. microRNAs with a role in cancer. Nat. Rev. Cancer 2006, 6(4):259-269.
259. The Innovative Medicines Initiative (IMI) (2006) Strategic research agenda "Creating Biomedical R&D Leadership for Europe to Benefit Patients and Society,". http://www.ebe-biopharma.org/documents/IMI/imi_strategicresagenda.pdf.
260. Atkinson A.J., Colburn W.A., Degruttola V.G., Demets D.L., Downing G.J., Hoth D.F., et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69(3):89-95.
261. Zhan X., Desiderio D.M. Signaling pathway networks mined from human pituitary adenoma proteomics data. BMC Med. Genomics 2010, 3:13.
262. Tainsky M.A. Genomic and proteomic biomarkers for cancer: A multitude of opportunities. Biochim. Biophys. Acta 2009, 1796(2):176-193.
263. Ley T.J., Mardis E.R., Ding L., Fulton B., Mclellan M.D., Chen K., et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008, 456(7218):66-72.
264. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
265. Leary R.J., Lin J.C., Cummins J., Boca S., Wood L.D., Parsons D.W., et al. Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:16224-16229.
266. Okuda S., Yamada T., Hamajima M.A., Itoh M., Katayama T., Bork P., et al. KEGG Atlas mapping for global analysis of metabolic pathways. Nucleic Acids Res. 2008, 36:W423-W426.
267. Segota I., Bartonicek N., Vlahovicek K. MADNet: Microarray database network web server. Nucleic Acids Res. 2008, 36:W332-W335.
268. Hoque M.O., Feng Q., Toure P., Dem A., Critchlow C.W., Hawes S.E., et al. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J. Clin. Oncol. 2006, 24:4262-4269.
269. Muraki Y., Banno K., Yanokura M., Kobayashi Y., Kawaguchi M., Nomura H., et al. Epigenetic DNA hypermethylation: Clinical applications in endometrial cancer. Oncol. Rep. 2009, 22(5):967-972.
270. Lawrie C.H., Gal S., Dunlop H.M., Pushkaran B., Liggins A.P., Pulford K., et al. Detection of elevated levels of tumor-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol. 2008, 141:672-675.
271. Roessler M., Rollinger W., Mantovani-Endl L., Hagmann M.L., Palme S., Berndt P., et al. Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis. Mol. Cell. Proteomics 2006, 5:2092-2101.
272. Martosella J., Zolotarjova N., Liu H., Nicol G., Boyes B.E. Reversed-phase high performance liquid chromatographic prefractionation of immunodepleted human serum proteins to enhance mass spectrometry identification of lower-abundant proteins. J. Proteome Res. 2005, 4:1522-1537.
273. Faca V., Coram M., Phanstiel D., Glukhova V., Zhang Q., Fitzgibbon M., et al. Quantitative analysis of acrylamide labeled serum proteins by LC-MS/MS. J. Proteome Res. 2006, 5:2009-2018.
274. Andreev V.P., Li L., Rejtar T., Li Q., Ferry J.G., Karger B.L. New algorithm for 15N/14N quantitation with LC-ESI-MS using an LTQ-FT mass spectrometer. J. Proteome Res. 2006, 5:2039-2045.
275. Merchant M., Weinberger S.R. Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 2000, 21:1164-1177.
276. Petricoin E.F., Zoon K.C., Kohn E.C., Barrett J.C., Liotta L.A. Clinical proteomics: Translating benchside promise into bedside reality. Nat. Rev. Drug Discov. 2002, 1:683-695.
277. Drake R.R., Schwegler E.E., Malik G., Diaz J., Block T., Mehta A., et al. Lectin capture strategies combined with mass spectrometry for the discovery of serum glycoprotein biomarkers. Mol. Cell. Proteomics 2006, 5:1957-1967.
278. Hanas J.S., Hocker J.R., Cheung J.Y., Larabee J.L., Lerner M.R., Lightfoot S.A., et al. Biomarker identification in human pancreatic cancer sera. Pancreas 2008, 36(1):61-69.
279. Haab B.B. Antibody arrays in cancer research. Mol. Cell. Proteomics 2005, 4:377-383.
280. Sanchez-Carbayo M., Socci N.D., Lozano J.J., Haab B.B., Cordon-Cardo C. Profiling bladder cancer using targeted antibody arrays. Am. J. Pathol. 2006, 168:93-103.
281. Qian X., Scheithauer B.W., Kovacs K., Lloyd R.V. DNA microarrays: Recent developments and applications to the study of pituitary tissues. Endocrine 2005, 28(1):49-56.
282. Farrell W.E. Pituitary tumours: Findings from whole genome analyses. Endocr. Relat. Cancer 2006, 13(3):707-716.
283. Jiang Z., Gui S., Zhang Y. Analysis of differential gene expression by fiber-optic BeadArray and pathway in prolactinomas. Endocrine 2010, 38(3):360-368.
284. Evans C.O., Moreno C.S., Zhan X., McCabe M.T., Vertino P.M., Desiderio D.M., et al. Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analyses. Pituitary 2008, 11(3):231-245.
285. Moreno C.S., Evans C.O., Zhan X., Okor M., Desiderio D.M., Oyesiku N.M. Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses. Cancer Res. 2005, 65(22):10214-10222.
286. Galland F., Lacroix L., Saulnier P., Dessen P., Meduri G., Bernier M., et al. Differential gene expression profiles of invasive and non-invasive non-functioning pituitary adenomas based on microarray analysis. Endocr. Relat. Cancer 2010, 17(2):361-371.
287. Zhan X., Desiderio D.M. A reference map of a human pituitary adenoma proteome. Proteomics 2003, 3(5):699-713.
288. Zhan X., Desiderio D.M. Heterogeneity analysis of the human pituitary proteome. Clin. Chem. 2003, 49(10):1740-1751.
289. Beranova-Giorgianni S., Giorgianni F., Desiderio D.M. Analysis of the proteome in the human pituitary. Proteomics 2002, 2(5):534-542.
290. Desiderio D.M., Zhan X. The human pituitary proteome: The characterization of differentially expressed proteins in an adenoma compared to a control. Cell. Mol. Biol. 2003, 49(5):689-712.
291. Zhan X., Evans C.O., Oyesiku N.M., Desiderio D.M. Proteomics and transcriptomics analyses of secretagogin down-regulation in human non-functional pituitary adenomas. Pituitary 2003, 6(4):189-202.
292. Zhan X., Desiderio D.M. Signaling pathway networks mined from human pituitary adenoma proteomics data. BMC Med. Genomics 2010, 3:13.
293. Kontogeorgos G., Kovacs K. Molecular Pathology of the Pituitary 2004, Karger, Basel.
294. Tanase C., Raducan E., Mihai S., Georgescu M., Ionita A., Poroschianu M., et al. Serum cytokines and growth factors levels in pituitary adenomas behaviour using Xmap technology. Virchows Arch. 2009, 455:S383.
295. Buchfelder M. Treatment of pituitary tumors. Endocrine 2005, 28(1):67-75.
296. Fahlbusch R., Keller B., Ganslandt O., Kreutzer J., Nimsky C. Transsphenoidal surgery in acromegaly investigated by intraoperative high-field magnetic resonance imaging. Eur. J. Endocrinol. 2005, 153(2):239-248.
297. Ghostine S., Ghostine M.S., Johnson W.D. Radiation therapy in the treatment of pituitary tumors. Neurosurg. Focus 2008, 25(5):1-5.
298. Molitch M.E., Grossmann A.B. Pituitary radiotherapy. Pituitary 2008, 12:1-2.
299. Ivan G., Syiegeti-Csucy N., Olah M. Treatment of pituitary tumors: Dopamine agonists. Endocrine 2005, 28(1):101-110.
300. Syro L.V., Kovacs K., Scheithauer B.W. Reply to treatment of pituitary neoplasms with temozolomide: A review. Cancer 2011, 117:4102.
301. Syro L.V., Uribe H., Penagos L.C., Ortiz L.D., Fadul C.E., Horvath E., et al. Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin. Endocrinol. (Oxf.) 2006, 65:552-553.
302. Kovacs K., Horvath E., Syro L.V., Uribe H., Penagos L.C., Ortiz L.D., et al. Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings. Hum. Pathol. 2007, 38:185-189.
303. Kovacs K., Scheithauer B.W., Lombardero M., McLendon R.E., Syro L.V., Uribe H., et al. MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol. 2008, 115:261-262.
304. Agarwala S.S., Kirkwood J.M. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 2000, 5:144-151.
305. McCormack A.I., McDonald K.L., Gill A.J., Clark S.J., Burt M.G., Campbell K.A., et al. Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin. Endocrinol. (Oxf.) 2009, 71:226-233.
306. Garcia-Echeverria C., Sellers W.R. Drug discovery approaches targeting the PI3K/AKT pathway in cancer. Oncogene 2008, 27(41):5511-5526.
307. Carnero A., Blanco-Aparicio C., Renner O., Link W., Leal J.F. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr. Cancer Drug Targets 2008, 8(3):187-198.
308. Vlotides G., Cruz-Soto M., Rubinek T., Eigler T., Auernhammer C.J., Melmed S. Mechanisms for growth factor-induced pituitary tumor transforming gene-1 expression in pituitary folliculostellate TtT/GF cells. Mol. Endocrinol. 2006, 20(12):3321-3335.
309. Vlotides G., Eigler T., Melmed S. Pituitary tumor-transforming gene: Physiology and implications for tumorigenesis. Endocr. Rev. 2007, 28(2):165-186.
310. Malumbres M., Pevarello P., Barbacid M., Bischoff J.R. CDK inhibitors in cancer therapy: What is next?. Trends Pharmacol. Sci. 2008, 29(1):16-21.
311. Perez de Castro I., de Carcer G., Malumbres M. A census of mitotic cancer genes: New insights into tumor cell biology and cancer therapy. Carcinogenesis 2007, 28(5):899-912.
312. Sotillo R., Renner O., Dubus P., Ruiz-Cabello J., Martín-Caballero J., Barbacid M., et al. Cooperation between Cdk4 and p27kip1 in tumor development: A preclinical model to evaluate cell cycle inhibitors with therapeutic activity. Cancer Res. 2005, 65(9):3846-3852.
313. Heaney A.P., Melmed S. Molecular targets in pituitary tumours. Nat. Rev. Cancer 2004, 4(4):285-295.
314. Kontogeorgos G. Classification and pathology of pituitary tumours. Endocrine 2005, 28(1):27-35.
315. Kontogeorgos G. Predictive markers of pituitary adenoma behavior. Neuroendocrinology 2006, 83(3-4):179-188.
316. Hubina E., Nanzer A.M., Hanson M.R., Ciccarelli E., Losa M., Gaia D., et al. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur. J. Endocrinol. 2006, 155(2):371-379.
317. Naor Z. Signalling by G-protein-coupled receptor (GPCR): Studies on the GnRH receptor. Front. Neuroendocrinol. 2009, 30(1):10-29.
318. Tanase C.P., Neagu M., Albulescu R. Key signaling molecules in pituitary tumors. Expert Rev. Mol. Diagn. 2009, 9(8):859-877.